News
Praxis Precision Medicines
PRAX · NASDAQ
$264.49+$4.32 (+1.66%)TodayMarket closed ·
Prev close $260.17
Latest news
- Press releaseGlobe Newswire
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
- Press releaseGlobe Newswire
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
- Press releaseGlobe Newswire
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
- NewsVandana Singh
Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
- Press releaseGlobe Newswire
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
- NewsVandana Singh
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
- Press releaseGlobe Newswire
Praxis Precision Medicines Provides Vormatrigine Program Update
- Press releaseGlobe Newswire
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
- NewsVandana Singh
Why Is Praxis Precision Stock Soaring Tuesday?
- Press releaseGlobe Newswire
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
- Press releaseGlobe Newswire
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
- NewsAvi Kapoor
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
- NewsAvi Kapoor
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results
- News
Earnings Breakdown: Praxis Precision Medicine Q4
- Press releaseGlobe Newswire
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
- News
Earnings Scheduled For February 19, 2026
- News
Earnings Outlook For Praxis Precision Medicine
- NewsAvi Kapoor
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- NewsAvi Kapoor
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
- NewsVandana Singh
Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next
- NewsAvi Kapoor
Crude Oil Moves Higher; Domo Shares Plunge
- News
Market-Moving News for December 5th
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsMohd Haider
Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?
- NewsVandana Singh
Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'
- NewsAvi Kapoor
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Dow Dips Over 100 Points; US Crude Oil Inventories Surge
- NewsAvi Kapoor
Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings
- NewsVandana Singh
Praxis Precision Medicines Stock Doubles - Here's Why
- News
Praxis Precision Reports Phase 3 Results for Ulixacaltamide in Essential Tremor
- Press releaseGlobe Newswire
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
- Press releaseBusiness Wire
ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update
- Press releaseGlobe Newswire
PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Is Investigating Praxis, Align, Lantheus, and Spirit and Encourages Investors to Contact the Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
- Press releaseGlobe Newswire
PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.